BioVie CEO Discusses Breakthrough Parkinson’s Trial Results and Phase 3 Plans

BioVie (NASDAQ: BIVI) President and CEO Cuong Do discusses the company’s encouraging Phase 2 clinical trial results for bezisterim in patients with early-stage Parkinson’s disease. The study demonstrated statistically significant improvements in both motor and non-motor symptoms, while also showing evidence that the therapy may help slow disease progression by reducing neurodegeneration and inflammation—an outcome that could represent a major advance in Parkinson’s treatment.

Do explains why these findings are significant, noting that current Parkinson’s therapies primarily address motor symptoms while bezisterim has the potential to become the first treatment targeting both motor and non-motor symptoms. He also outlines the company’s next steps, including an End-of-Phase 2 meeting with the FDA, preparations for a potentially pivotal Phase 3 trial, ongoing data analysis, and upcoming topline results from BioVie’s Long COVID clinical program.

#BioVie
#BIVI
#ParkinsonsDisease
#Bezisterim
#ClinicalTrials
#Biotechnology
#Neurology
#NeurodegenerativeDisease
#LongCOVID
#DrugDevelopment
#HealthcareInnovation
#NASDAQ
#JaneKing
#NewsOut
#MedicalResearch